Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

According to the company, the patents cover "methods for the algorithms used and methods utilizing genes beyond the current 21 gene set."

Testing colorectal cancer patients for their UGT1A1*28 status before prescribing irinotecan is cost-effective only when reduced doses of the drug are as effective as full doses in patients who are homozygous for the variant.

Pfizer enlisted the help of Ontario researchers to find molecular signatures that can be used to personalize treatments in its pipeline for colorectal cancer.

In order to make the labeling change, the agency reviewed retrospective data from seven clinical trials. But this is the exception, according to one official from a diagnostic company who believes FDA's lengthy deliberations have further nudged drug companies to advance diagnostics at the same time as therapeutics in prospective studies.

The FDA has updated the drugs' labels to note that "retrospective analyses of metastatic colorectal cancer trials have not shown a treatment benefit for the EGFR inhibitors in patients whose tumors had KRAS mutations in codon 12 or 13" and that the use of the drugs is not recommended for the treatment of colorectal cancer patients with these mutations.

Even though Genomic Health's Oncotype DX recurrence test for colorectal cancer failed to meet its chemotherapy benefit endpoint, investment group Thomas Wiesel is optimistic after a survey of 47 physicians and researcher that the strength of the Oncotype DX brand and the lack of molecular profiling options in the colorectal cancer setting will drive adoption of the test.

New Releases: Jul 8, 2009


Exiqon's BRAF mutation analysis

Exact gained exclusive rights to technology developed by the Mayo Clinic's David Ahlquist relating to sample processing, analytical testing, and data analysis for non-invasive, stool-based DNA screening for colorectal cancer.

Quest plans to develop colorectal cancer-related genetic markers for a diagnostic test.

CEO David Deems said that Xceed has decided to engage the FDA early in the development process because the agency's "thinking on these types of tests is evolving" and the company would like to "stay connected to whatever approach they are thinking of putting in place."


Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.